Target Validation Information
TTD ID T02551
Target Name Dopamine D3 receptor (D3R)
Type of Target
Successful
Drug Potency against Target Pramipexole Drug Info Ki = 0.5 nM [41]
Ropinirole Drug Info Ki = 4.37 nM [46]
BP4.879a Drug Info IC50 = 5 nM [44]
BTS-79018 Drug Info Ki = 1.6 nM [42]
PD-158771 Drug Info Ki = 13.7 nM [47]
Sarizotan Drug Info IC50 = 0.1 nM [45]
(+)-BUTACLAMOL Drug Info IC50 = 6.6 nM [18]
(+/-)-nantenine Drug Info Ki = 309 nM [24]
(-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile Drug Info Ki = 249 nM [36]
(2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine Drug Info Ki = 4654 nM [5]
(4-Dipropylamino-cyclohexylidene)-acetonitrile Drug Info Ki = 13000 nM [3]
(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine Drug Info Ki = 190 nM [17]
(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine Drug Info Ki = 3500 nM [3]
(R)-(-)-2-Methyl-apomorphine hydrochloride Drug Info Ki = 40.1 nM [15]
(R)-(-)-2-Phenyl-apomorphine hydrochloride Drug Info Ki = 7.7 nM [15]
(R)-2-(Benzylamino-methyl)-chroman-7-ol Drug Info Ki = 2.4 nM [4]
1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine Drug Info Ki = 2100 nM [9]
1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one Drug Info Ki = 195 nM [11]
1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine Drug Info Ki = 7900 nM [2]
1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine Drug Info Ki = 2600 nM [2]
1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine Drug Info Ki = 770 nM [2]
1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine Drug Info Ki = 6800 nM [2]
1-Benzyl-4-pyrrol-1-yl-piperidine Drug Info Ki = 15000 nM [2]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine Drug Info IC50 = 1500 nM [32]
1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine Drug Info Ki = 35 nM
1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine Drug Info Ki = 7804 nM [5]
1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine Drug Info Ki = 1818 nM [5]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine Drug Info Ki = 2923 nM [5]
2-(4-Dipropylamino-cyclohexylidene)-malononitrile Drug Info Ki = 1600 nM [3]
3-(1-Propyl-pyrrolidin-3-yl)-phenol Drug Info Ki = 52 nM
3-(2-Benzylamino-ethoxy)-phenol Drug Info Ki = 11 nM [1]
3-(4-Benzyl-piperazin-1-yl)-phenol Drug Info Ki = 28.9 nM [40]
3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole Drug Info Ki = 6700 nM [37]
3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole Drug Info Ki = 280 nM [37]
3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole Drug Info Ki = 95 nM [37]
4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one Drug Info Ki = 2.8 nM [1]
4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole Drug Info Ki = 870.5 nM [40]
4-(4-Benzyl-piperazin-1-yl)-1H-indole Drug Info Ki = 35.4 nM [40]
4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole Drug Info Ki = 95.3 nM [40]
4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole Drug Info Ki = 56 nM [40]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki < 1000 nM [28]
4-Dipropylamino-cyclohex-1-enecarbonitrile Drug Info Ki = 13000 nM [3]
5-OH-DPAT Drug Info Ki = 1.36 nM [25]
A-437203 Drug Info Ki = 2.9 nM [8]
A-690344 Drug Info Ki = 1.3 nM [8]
A-706149 Drug Info Ki = 0.8 nM [7]
Azaperone Drug Info Ki = 53 nM [34]
Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine Drug Info Ki = 8.8 nM [1]
Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine Drug Info Ki = 19.5 nM [1]
BP-897 Drug Info Ki = 20.2 nM [27]
D-189 Drug Info Ki = 46.7 nM [16]
D-190 Drug Info Ki = 40.7 nM [16]
D-192 Drug Info Ki = 254 nM [16]
D-193 Drug Info Ki = 155 nM [16]
D-203 Drug Info Ki = 12.4 nM [16]
D-210 Drug Info Ki = 5.09 nM [16]
D-218 Drug Info Ki = 34.8 nM [16]
D-219 Drug Info Ki = 1.82 nM [16]
D-220 Drug Info Ki = 7.1 nM [16]
D-264 Drug Info Ki = 0.92 nM [21]
D-315 Drug Info Ki = 1.77 nM [26]
D-366 Drug Info Ki = 0.57 nM [25]
Etoloxamine Drug Info Ki = 4667 nM [5]
FLUMEZAPINE Drug Info IC50 = 20 nM [31]
FLUTROLINE Drug Info IC50 = 14 nM [30]
GR-218231 Drug Info Ki = 1.3 nM [20]
ISOCLOZAPINE Drug Info IC50 = 758 nM [32]
ISOLOXAPINE Drug Info IC50 = 2480 nM [33]
L-741626 Drug Info Ki = 104 nM
L-741742 Drug Info Ki = 770 nM [38]
Levacecarnine hci Drug Info Ki = 8.72 nM [13]
MAZAPERTINE Drug Info Ki = 1.8 nM [35]
N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide Drug Info Ki = 950 nM [17]
N-(4-Propylaminobutyl)-4-biphenylcarboxamide Drug Info Ki = 11000 nM [17]
NLX-101 Drug Info Ki = 10000 nM [29]
PG-01037 Drug Info IC50 = 3 nM [12]
QUINPIROLE Drug Info Ki = 49 nM [23]
R-226161 Drug Info Ki = 375 nM [10]
SB-271046 Drug Info Ki = 1330 nM [14]
STEPHOLIDINE Drug Info Ki = 30 nM [22]
Sumanirole Drug Info Ki = 2333 nM [39]
UH-232 Drug Info Ki = 4.2 nM
[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine Drug Info Ki = 67.2 nM [1]
[3H]7-OH-DPAT Drug Info Ki = 6.19 nM [19]
[3H]spiperone Drug Info Ki = 0.25 nM [6]
Action against Disease Model Pramipexole Drug Info EC50 in terminally differentiated neuroblastoma SH-SY5Y: 64300nM [43]
References
REF 1 New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
REF 2 Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
REF 3 Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
REF 4 Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybri... J Med Chem. 2003 Oct 9;46(21):4377-92.
REF 5 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
REF 6 Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. J Med Chem. 2005 Feb 10;48(3):694-709.
REF 7 Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.genes... Bioorg Med Chem Lett. 2006 Feb;16(3):658-62.
REF 8 Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):490-4.
REF 9 Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.
REF 10 Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
REF 11 Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Bioorg Med Chem. 2007 Sep 1;15(17):5811-8.
REF 12 Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
REF 13 Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR liga... Bioorg Med Chem. 2007 Dec 1;15(23):7258-73.
REF 14 Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
REF 15 Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9.
REF 16 Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19.
REF 17 Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
REF 18 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
REF 19 Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19.
REF 20 Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of t... Bioorg Med Chem. 2009 Jan 15;17(2):758-66.
REF 21 Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-... Bioorg Med Chem. 2009 Jun 1;17(11):3923-33.
REF 22 Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
REF 23 1,1'-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands. J Med Chem. 2009 Nov 12;52(21):6860-70.
REF 24 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
REF 25 Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37.
REF 26 Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template... Bioorg Med Chem. 2010 Aug 1;18(15):5661-74.
REF 27 Synthesis and in vitro binding studies of piperazine-alkyl-naphthamides: impact of homology and sulphonamide/carboxamide bioisosteric replacement o... Bioorg Med Chem Lett. 2010 Sep 1;20(17):5199-202.
REF 28 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
REF 29 Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists. J Med Chem. 2010 Oct 14;53(19):7167-79.
REF 30 Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
REF 31 Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
REF 32 Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
REF 33 Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
REF 34 Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem. 1993 Nov 26;36(24):3929-36.
REF 35 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
REF 36 Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J Med Chem. 1993 Oct 15;36(21):3188-96.
REF 37 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
REF 38 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5.
REF 39 Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. J Med Chem. 1997 Feb 28;40(5):639-46.
REF 40 New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
REF 41 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
REF 42 N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents. J Med Chem. 1999 Aug 26;42(17):3342-55.
REF 43 Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp Neurol. 2004 Nov;190(1):157-70.
REF 44 5-HT3 receptors. Curr Pharm Des. 2006;12(28):3615-30.
REF 45 5-HT1A receptor, an old target for new therapeutic agents. Curr Top Med Chem. 2008;8(12):1024-34.
REF 46 Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
REF 47 Aminopyrimidines with high affinity for both serotonin and dopamine receptors. J Med Chem. 1998 Feb 26;41(5):760-71.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.